<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04870000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q05397</UniProt_ID>
  <Seq_Length>1052</Seq_Length>
  <Molecule_Weight>119233</Molecule_Weight>
  <KEGG_ID>hsa:5747</KEGG_ID>
  <Orthology_ID>K05725</Orthology_ID>
  <EBI_ID>EBI-702142</EBI_ID>
  <Function_Summary>Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. Required for early embryonic development and placenta development. Required for embryonic angiogenesis, normal cardiomyocyte migration and proliferation, and normal heart development. Regulates axon growth and neuronal cell migration, axon branching and synapse formation; required for normal development of the nervous system. Plays a role in osteogenesis and differentiation of osteoblasts. Functions in integrin signal transduction, but also in signaling downstream of numerous growth factor receptors, G-protein coupled receptors (GPCR), EPHA2, netrin receptors and LDL receptors. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascade. Promotes activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling cascade. Promotes localized and transient activation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), and thereby modulates the activity of Rho family GTPases. Signaling via CAS family members mediates activation of RAC1. Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ACTN1, ARHGEF7, GRB7, RET and WASL. Promotes phosphorylation of PXN and STAT1; most likely PXN and STAT1 are phosphorylated by a SRC family kinase that is recruited to autophosphorylated PTK2/FAK1, rather than by PTK2/FAK1 itself. Promotes phosphorylation of BCAR1; GIT2 and SHC1; this requires both SRC and PTK2/FAK1. Promotes phosphorylation of BMX and PIK3R1. Isoform 6 (FRNK) does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation and signaling. Its enhanced expression can attenuate the nuclear accumulation of LPXN and limit its ability to enhance serum response factor (SRF)-dependent gene transcription.</Function_Summary>
  <Catalytic_Mechanism>ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF00373:FERM_M@@PF03623:Focal_AT@@PF07714:Pkinase_Tyr</Pfam_ID>
  <Allosteric_Activator_Count>2</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>4</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>p125FAK</Alias>
      <Alias>pp125FAK</Alias>
      <Alias>Protein phosphatase 1 regulatory subunit 71</Alias>
      <Alias>Focal adhesion kinase-related nonkinase</Alias>
      <Alias>Protein-tyrosine kinase 2</Alias>
      <Alias>FADK 1</Alias>
      <Alias>FRNK</Alias>
      <Alias>PPP1R71</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with JUN kinase, an enzyme that catalyzes the phosphorylation and activation of members of the JUN family.</Detail>
      <Keyword>JUN kinase binding</Keyword>
      <Ontology_ID>GO:0008432</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Conveys a signal across a cell to trigger a change in cell function or state. A signal is a physical entity or change in state that is used to transfer information in order to trigger a response.</Detail>
      <Keyword>Signal transducer activity</Keyword>
      <Ontology_ID>GO:0004871</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a SH2 domain (Src homology 2) of a protein, a protein domain of about 100 amino-acid residues and belonging to the alpha + beta domain class.</Detail>
      <Keyword>SH2 domain binding</Keyword>
      <Ontology_ID>GO:0042169</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a non-membrane spanning protein L-tyrosine = ADP + a non-membrane spanning protein L-tyrosine phosphate.</Detail>
      <Keyword>Non-membrane spanning protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004715</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>1044</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>292</Position>
      <Original>His</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>292</Position>
      <Original>His</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>793</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>1030</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The breakdown of structures such as organelles, proteins, or other macromolecular structures during apoptosis.</Detail>
      <Keyword>Cellular component disassembly involved in apoptosis</Keyword>
      <Ontology_ID>GO:0006921</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of protein ubiquitination involved in ubiquitin-dependent protein catabolic process.</Detail>
      <Keyword>Positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process</Keyword>
      <Ontology_ID>GO:2000060</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The developmental process in which the heart is generated and organized. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood.</Detail>
      <Keyword>Heart morphogenesis</Keyword>
      <Ontology_ID>GO:0003007</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation of peptidyl-tyrosine to form peptidyl-O4'-phospho-L-tyrosine.</Detail>
      <Keyword>Peptidyl-tyrosine phosphorylation</Keyword>
      <Ontology_ID>GO:0018108</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the surface configuration of a cell.</Detail>
      <Keyword>Regulation of cell shape</Keyword>
      <Ontology_ID>GO:0008360</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.</Detail>
      <Keyword>Regulation of endothelial cell migration</Keyword>
      <Ontology_ID>GO:0010594</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of an embryo from its formation until the end of its embryonic life stage. The end of the embryonic stage is organism-specific. For example, for mammals, the process would begin with zygote formation and end with birth. For insects, the process would begin at zygote formation and end with larval hatching. For plant zygotic embryos, this would be from zygote formation to the end of seed dormancy. For plant vegetative embryos, this would be from the initial determination of the cell or group of cells to form an embryo until the point when the embryo becomes independent of the parent plant.</Detail>
      <Keyword>Embryo development</Keyword>
      <Ontology_ID>GO:0009790</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate, or extent of cell adhesion mediated by integrin.</Detail>
      <Keyword>Regulation of cell adhesion mediated by integrin</Keyword>
      <Ontology_ID>GO:0033628</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin.</Detail>
      <Keyword>Placenta development</Keyword>
      <Ontology_ID>GO:0001890</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell migration.</Detail>
      <Keyword>Positive regulation of cell migration</Keyword>
      <Ontology_ID>GO:0030335</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The biological process whose specific outcome is the progression of a multicellular organism over time from an initial condition (e.g. a zygote or a young adult) to a later condition (e.g. a multicellular animal or an aged adult).</Detail>
      <Keyword>Multicellular organismal development</Keyword>
      <Ontology_ID>GO:0007275</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures.</Detail>
      <Keyword>Regulation of cytoskeleton organization</Keyword>
      <Ontology_ID>GO:0051493</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The specification and formation of anisotropic intracellular organization or cell growth patterns.</Detail>
      <Keyword>Establishment of cell polarity</Keyword>
      <Ontology_ID>GO:0030010</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of growth hormone receptor binding to its physiological ligand.</Detail>
      <Keyword>Growth hormone receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0060396</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another.</Detail>
      <Keyword>Cell motility</Keyword>
      <Ontology_ID>GO:0048870</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of an ephrin receptor binding to an ephrin.</Detail>
      <Keyword>Ephrin receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0048013</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation by a protein of one or more of its own amino acid residues, or residues on an identical protein.</Detail>
      <Keyword>Protein autophosphorylation</Keyword>
      <Ontology_ID>GO:0046777</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the activity of a GTPase of the Rho family.</Detail>
      <Keyword>Regulation of Rho GTPase activity</Keyword>
      <Ontology_ID>GO:0032319</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of osteoblast differentiation.</Detail>
      <Keyword>Regulation of osteoblast differentiation</Keyword>
      <Ontology_ID>GO:0045667</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of focal adhesion formation, the establishment and maturation of focal adhesions.</Detail>
      <Keyword>Regulation of focal adhesion assembly</Keyword>
      <Ontology_ID>GO:0051893</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the protein kinase B signaling cascade, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.</Detail>
      <Keyword>Positive regulation of protein kinase B signaling cascade</Keyword>
      <Ontology_ID>GO:0051897</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of cell proliferation.</Detail>
      <Keyword>Positive regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008284</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.</Detail>
      <Keyword>Positive regulation of protein phosphorylation</Keyword>
      <Ontology_ID>GO:0001934</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.</Detail>
      <Keyword>Angiogenesis</Keyword>
      <Ontology_ID>GO:0001525</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of phosphatidylinositol 3-kinase activity.</Detail>
      <Keyword>Positive regulation of phosphatidylinositol 3-kinase activity</Keyword>
      <Ontology_ID>GO:0043552</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the phosphatidylinositol 3-kinase cascade.</Detail>
      <Keyword>Positive regulation of phosphatidylinositol 3-kinase cascade</Keyword>
      <Ontology_ID>GO:0014068</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of protein kinase activity.</Detail>
      <Keyword>Positive regulation of protein kinase activity</Keyword>
      <Ontology_ID>GO:0045860</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of an integrin binding to one of its physiological ligands.</Detail>
      <Keyword>Integrin-mediated signaling pathway</Keyword>
      <Ontology_ID>GO:0007229</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemotaxis process that directs the migration of an axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.</Detail>
      <Keyword>Axon guidance</Keyword>
      <Ontology_ID>GO:0007411</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The aggregation, arrangement and bonding together of a set of components to form a complex capable of relaying a signal within a cell. Complex formation involves dimerization of a receptor protein tyrosine kinase followed by the association of several different intracellular signaling molecules with the cytoplasmic tails of the receptors.</Detail>
      <Keyword>Signal complex assembly</Keyword>
      <Ontology_ID>GO:0007172</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents or reduces the rate or extent of cell adhesion to another cell.</Detail>
      <Keyword>Negative regulation of cell-cell adhesion</Keyword>
      <Ontology_ID>GO:0022408</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>13</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>843</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>732</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>576</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>29</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>910</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>386</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>887</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>705</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>394</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>708</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>702</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>861</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>722</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>2</Position>
      <PTM_Type>N-acetylalanine</PTM_Type>
    </PTM>
    <PTM>
      <Position>5</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>406</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>925</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>568</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>392</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>575</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>390</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>16</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>570</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>700</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>716</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>397</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>840</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>720</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>577</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>677</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>580</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>407</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MAAAYLDPNLNHTPNSSTKTHLGTGMERSPGAMERVLKVFHYFESNSEPTTWASIIRHGDATDVRGIIQKIVDSHKVKHVACYGFRLSHLRSEEVHWLHVDMGVSSVREKYELAHPPEEWKYELRIRYLPKGFLNQFTEDKPTLNFFYQQVKSDYMLEIADQVDQEIALKLGCLEIRRSYWEMRGNALEKKSNYEVLEKDVGLKRFFPKSLLDSVKAKTLRKLIQQTFRQFANLNREESILKFFEILSPVYRFDKECFKCALGSSWIISVELAIGPEEGISYLTDKGCNPTHLADFTQVQTIQYSNSEDKDRKGMLQLKIAGAPEPLTVTAPSLTIAENMADLIDGYCRLVNGTSQSFIIRPQKEGERALPSIPKLANSEKQGMRTHAVSVSETDDYAEIIDEEDTYTMPSTRDYEIQRERIELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKLIGVITENPVWIIMELCTLGELRSFLQVRKYSLDLASLILYAYQLSTALAYLESKRFVHRDIAARNVLVSSNDCVKLGDFGLSRYMEDSTYYKASKGKLPIKWMAPESINFRRFTSASDVWMFGVCMWEILMHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTILEEEKAQQEERMRMESRRQATVSWDSGGSDEAPPKPSRPGYPSPRSSEGFYPSPQHMVQTNHYQVSGYPGSHGITAMAGSIYPGQASLLDQTDSWNHRPQEIAMWQPNVEDSTVLDLRGIGQVLPTHLMEERLIRQQQEMEEDQRWLEKEERFLKPDVRLSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPKKPPRPGAPGHLGSLASLSSPADSYNEGVKLQPQEISPPPTANLDRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGLALRTLLATVDETIPLLPASTHREIEMAQKLLNSDLGELINKMKLAQQYVMTSLQQEYKKQMLTAAHALAVDAKNLLDVIDQARLKMLGQTRPH</Protein_Seq>
    <DNA_Seq>GCGCACGCGCGCGGGCCCGCGCCGACGCAGCACGGCCTCGAGGGCGCGAGCCCGCGCCGCCGCCGCCGCCGCCGGTCCCGGACCACTGTGAGCCCGCGGCGTGAGGCGTGGGAGGAAGCGCGGCTGCTGTCGCCCAGCGCCGCCCCGTCGTCGTCTGCCTTCGCTTCACGGCGCCGAGCCGCGGTCCGAGCAGAACTGGGGCTCCCTTGCATCTTCCAGTTACAAATTCAGTGCCTTCTGCAGTTTCCCCAGAGCTCCTCAAGAATAACGGAAGGGAGAATATGACAGATACCTAGCATCTAGCAAAATAATGGCAGCTGCTTACCTTGACCCCAACTTGAATCACACACCAAATTCGAGTACTAAGACTCACCTGGGTACTGGTATGGAACGTTCTCCTGGTGCAATGGAGCGAGTATTAAAGGTCTTTCATTATTTTGAAAGCAATAGTGAGCCAACCACCTGGGCCAGTATTATCAGGCATGGAGATGCTACTGATGTCAGGGGCATCATTCAGAAGATAGTGGACAGTCACAAAGTAAAGCATGTGGCCTGCTATGGATTCCGCCTCAGTCACCTGCGGTCAGAGGAGGTTCACTGGCTTCACGTGGATATGGGCGTCTCCAGTGTGAGGGAGAAGTATGAGCTTGCTCACCCACCAGAGGAGTGGAAATATGAATTGAGAATTCGTTATTTGCCAAAAGGATTTCTAAACCAGTTTACTGAAGATAAGCCAACTTTGAATTTCTTCTATCAACAGGTGAAGAGCGATTATATGTTAGAGATAGCTGATCAAGTGGACCAGGAAATTGCTTTGAAGTTGGGTTGTCTAGAAATACGGCGATCATACTGGGAGATGCGGGGCAATGCACTAGAAAAGAAGTCTAACTATGAAGTATTAGAAAAAGATGTTGGTTTAAAGCGATTTTTTCCTAAGAGTTTACTGGATTCTGTCAAGGCCAAAACACTAAGAAAACTGATCCAACAAACATTTAGACAATTTGCCAACCTTAATAGAGAAGAAAGTATTCTGAAATTCTTTGAGATCCTGTCTCCAGTCTACAGATTTGATAAGGAATGCTTCAAGTGTGCTCTTGGTTCAAGCTGGATTATTTCAGTGGAACTGGCAATCGGCCCAGAAGAAGGAATCAGTTACCTAACGGACAAGGGCTGCAATCCCACACATCTTGCTGACTTCACTCAAGTGCAAACCATTCAGTATTCAAACAGTGAAGACAAGGACAGAAAAGGAATGCTACAACTAAAAATAGCAGGTGCACCCGAGCCTCTGACAGTGACGGCACCATCCCTAACCATTGCGGAGAATATGGCTGACCTAATAGATGGGTACTGCCGGCTGGTGAATGGAACCTCGCAGTCATTTATCATCAGACCTCAGAAAGAAGGTGAACGGGCTTTGCCATCAATACCAAAGTTGGCCAACAGCGAAAAGCAAGGCATGCGGACACACGCCGTCTCTGTGTCAGAAACAGATGATTATGCTGAGATTATAGATGAAGAAGATACTTACACCATGCCCTCAACCAGGGATTATGAGATTCAAAGAGAAAGAATAGAACTTGGACGATGTATTGGAGAAGGCCAATTTGGAGATGTACATCAAGGCATTTATATGAGTCCAGAGAATCCAGCTTTGGCGGTTGCAATTAAAACATGTAAAAACTGTACTTCGGACAGCGTGAGAGAGAAATTTCTTCAAGAAGCCTTAACAATGCGTCAGTTTGACCATCCTCATATTGTGAAGCTGATTGGAGTCATCACAGAGAATCCTGTCTGGATAATCATGGAGCTGTGCACACTTGGAGAGCTGAGGTCATTTTTGCAAGTAAGGAAATACAGTTTGGATCTAGCATCTTTGATCCTGTATGCCTATCAGCTTAGTACAGCTCTTGCATATCTAGAGAGCAAAAGATTTGTACACAGGGACATTGCTGCTCGGAATGTTCTGGTGTCCTCAAATGATTGTGTAAAATTAGGAGACTTTGGATTATCCCGATATATGGAAGATAGTACTTACTACAAAGCTTCCAAAGGAAAATTGCCTATTAAATGGATGGCTCCAGAGTCAATCAATTTTCGACGTTTTACCTCAGCTAGTGACGTATGGATGTTTGGTGTGTGTATGTGGGAGATACTGATGCATGGTGTGAAGCCTTTTCAAGGAGTGAAGAACAATGATGTAATCGGTCGAATTGAAAATGGGGAAAGATTACCAATGCCTCCAAATTGTCCTCCTACCCTCTACAGCCTTATGACGAAATGCTGGGCCTATGACCCCAGCAGGCGGCCCAGGTTTACTGAACTTAAAGCTCAGCTCAGCACAATCCTGGAGGAAGAGAAGGCTCAGCAAGAAGAGCGCATGAGGATGGAGTCCAGAAGACAGGCCACAGTGTCCTGGGACTCCGGAGGGTCTGATGAAGCACCGCCCAAGCCCAGCAGACCGGGTTATCCCAGTCCGAGGTCCAGCGAAGGATTTTATCCCAGCCCACAGCACATGGTACAAACCAATCATTACCAGGTTTCTGGCTACCCTGGTTCACATGGAATCACAGCCATGGCTGGCAGCATCTATCCAGGTCAGGCATCTCTTTTGGACCAAACAGATTCATGGAATCATAGACCTCAGGAGATAGCAATGTGGCAGCCCAATGTGGAGGACTCTACAGTATTGGACCTGCGAGGGATTGGGCAAGTGTTGCCAACCCATCTGATGGAAGAGCGTCTAATCCGACAGCAACAGGAAATGGAAGAAGATCAGCGCTGGCTGGAAAAAGAGGAAAGATTTCTGAAACCTGATGTGAGACTCTCTCGAGGCAGTATTGACAGGGAGGATGGAAGTCTTCAGGGTCCGATTGGAAACCAACATATATATCAGCCTGTGGGTAAACCAGGTAAAGAAGAAAAGAATTGGGCGGAAAGAAATCCTGCAGCTCCACCAAAGAAACCGCCTCGCCCTGGAGCTCCCGGTCATCTGGGAAGCCTTGCCAGCCTCAGCAGCCCTGCTGACAGCTACAACGAGGGTGTCAAGCCATGGAGGCTTCAGCCCCAGGAAATCAGCCCCCCTCCTACTGCCAACCTGGACCGGTCGAATGATAAGGTGTACGAGAATGTGACGGGCCTGGTGAAAGCTGTCATCGAGATGTCCAGTAAAATCCAGCCAGCCCCACCAGAGGAGTATGTCCCTATGGTGAAGGAAGTCGGCTTGGCCCTGAGGACATTATTGGCCACTGTGGATGAGACCATTCCCCTCCTACCAGCCAGCACCCACCGAGAGATTGAGATGGCACAGAAGCTATTGAACTCTGACCTGGGTGAGCTCATCAACAAGATGAAACTGGCCCAGCAGTATGTCATGACCAGCCTCCAGCAAGAGTACAAAAAGCAAATGCTGACTGCTGCTCACGCCCTGGCTGTGGATGCCAAAAACTTACTCGATGTCATTGACCAAGCAAGACTGAAAATGCTTGGGCAGACGAGACCACACTGAGCCTCCCCTAGGAGCACGTCTTGCTACCCTCTTTTGAAGATGTTCTCTAGCCTTCCACCAGCAGCGAGGAATTAACCCTGTGTCCTCAGTCGCCAGCACTTACAGCTCCAACTTTTTTGAATGACCATCTGGTTGAAAAATCTTTCTCATATAAGTTTAACCACACTTTGATTTGGGTTCATTTTTTGTTTTGTTTTTTTCAATCATGATATTCAGAAAAATCCAGGATCCAAAATGTGGCGTTTTTCTAAGAATGAAAATTATATGTAAGCTTTTAAGCATCATGAAGAACAATTTATGTTCACATTAAGATACGTTCTAAAGGGGGATGGCCAAGGGGTGACATCTTAATTCCTAAACTACCTTAGCTGCATAGTGGAAGAGGAGAGCATGAAGCAAAGAATTCCAGGAAACCCAAGAGGCTGAGAATTCTTTTGTCTACCATAGAATTATTATCCAGACTGGAATTTTTGTTTGTTAGAACACCCTTCAGTTGCAATATGCTAATCCCACTTTACAAAGAATATAAAAGCTATATTTTGAAGACTTGAGTTATTTCAGAAAAAACTACAGCCCTTTTTGTCTTACCTGCCTTTTACTTTCGTGTGGATATGTGAAGCATTGGGTCGGGAACTAGCTGTAGAACACAACTAAAAACTCATGTCTTTTTTCACAGAATAATGTGCCAGTTTTTTGTAGCAATGTTATTTCTCTTGGAAGCAGAAATGCTTTGTACCAGAGCACCTCCAAACTGCATTGAGGAGAAGTTCCAGAACCATCCCCTTTTTCCATTTTTATATAATTTATAAAGAAAGATTAAAGCCATGTTGACTATTTTACAGCCACTGGAGTTAACTAACCCTTCCTTGTATCTGTCTTCCCAGGAGAGAATGAAGCAAAACAGGAATTTGGTTTTCTTTTGATGTCCAGTTACACCATCCATTCTGTTAATTTTGAAAAAATATACCCTCCCTTTAGTTTGTTGGGGGATATAAATTATTCTCAGGAAGAATATAATGAACTGTACAGTTACTTTGACCTATTAAAAAGGTGTTACCAGTAAAGTTCTTGTTGTAATATCCTTAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Widely expressed</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell junction</CellLocal>
      <Ontology_ID>GO:0030054</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Focal adhesion</CellLocal>
      <Ontology_ID>GO:0005925</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Microtubule organizing center</CellLocal>
      <Ontology_ID>GO:0005815</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell cortex</CellLocal>
      <Ontology_ID>GO:0005938</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoskeleton</CellLocal>
      <Ontology_ID>GO:0005856</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>PTK2</Gene_Name>
    <Gene_Alias>FAK; FAK1</Gene_Alias>
    <Gene_ID>5747</Gene_ID>
    <Genbank_ACCN>NM_001199649</Genbank_ACCN>
    <Protein_ACCN>NP_001186578</Protein_ACCN>
    <HGNC_ID>9611</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5747</Gene_URL>
    <UCSC_ID>uc003yvu.3</UCSC_ID>
    <EMBL_ID>ENSG00000169398</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P29317</Uniprot_ID>
      <Gene_Name>EPHA2</Gene_Name>
      <EBI_ID>EBI-702104</EBI_ID>
      <PPI_EBI_URL>EBI-702142,EBI-702104</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q62219</Uniprot_ID>
      <Gene_Name>Tgfb1i1</Gene_Name>
      <EBI_ID>EBI-642844</EBI_ID>
      <PPI_EBI_URL>EBI-702142,EBI-642844</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P04637</Uniprot_ID>
      <Gene_Name>TP53</Gene_Name>
      <EBI_ID>EBI-366083</EBI_ID>
      <PPI_EBI_URL>EBI-702142,EBI-366083</PPI_EBI_URL>
      <Experiment_Number>11</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P49023</Uniprot_ID>
      <Gene_Name>PXN</Gene_Name>
      <EBI_ID>EBI-702209</EBI_ID>
      <PPI_EBI_URL>EBI-702142,EBI-702209</PPI_EBI_URL>
      <Experiment_Number>7</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P12931</Uniprot_ID>
      <Gene_Name>SRC</Gene_Name>
      <EBI_ID>EBI-621482</EBI_ID>
      <PPI_EBI_URL>EBI-702142,EBI-621482</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q68CZ2</Uniprot_ID>
      <Gene_Name>TNS3</Gene_Name>
      <EBI_ID>EBI-1220488</EBI_ID>
      <PPI_EBI_URL>EBI-702142,EBI-1220488</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Scar Contracture</Disease_Name>
      <Disease_Detail>Scar Contracture</Disease_Detail>
      <Disease_DB>SCR033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/scar_contracture?search=PTK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=PTK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Askin's Tumor</Disease_Name>
      <Disease_Detail>Askin's Tumor</Disease_Detail>
      <Disease_DB>ASK001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/askins_tumor?search=PTK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastroesophageal Junction Adenocarcinoma</Disease_Name>
      <Disease_Detail>Gastroesophageal Junction Adenocarcinoma</Disease_Detail>
      <Disease_DB>GST012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastroesophageal_junction_adenocarcinoma?search=PTK2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal Structure of the Focal Adhesion Targeting Domain of Focal Adhesion Kinase</PDB_Title>
      <PDB_ID>1K04</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1K04</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structural basis of localization and signaling by the focal adhesion targeting domain.</PubMed_Title>
      <Author>Arold, S.T., et al.</Author>
      <Journal>Structure(2002)10:319-327</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12005431?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Focal Adhesion Kinase Domain Complexed with 7H-Pyrrolo [2,3-d] pyrimidine Derivative</PDB_Title>
      <PDB_ID>2ETM</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ETM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of Focal Adhesion Kinase Domain Complexed with ATP and novel 7H-Pyrrolo [2,3-d] pyrimidine scaffolds</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Paxillin LD4 motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase</PDB_Title>
      <PDB_ID>1OW6</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OW6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular Recognition of Paxillin LD motifs    by the Focal Adhesion Targeting Domain</PubMed_Title>
      <Author>Hoellerer, M.K., et al.</Author>
      <Journal>Structure(2003)11:1207-1217</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14527389?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the Focal Adhesion Targeting Domain of Focal Adhesion Kinase</PDB_Title>
      <PDB_ID>1K05</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1K05</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structural basis of localization and signaling by the focal adhesion targeting domain.</PubMed_Title>
      <Author>Arold, S.T., et al.</Author>
      <Journal>Structure(2002)10:319-327</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12005431?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH Pyrrolo[2,3-d]thiazole</PDB_Title>
      <PDB_ID>3PXK</PDB_ID>
      <Resolution>1.79</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PXK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Co-crystal Structures of FAK with an Unprecedented Pyrrolo[2,3-d]thiazole</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Analysis of Focal Adhesion Kinase with a Methanesulfonamide Diaminopyrimidine Inhibitor</PDB_Title>
      <PDB_ID>3BZ3</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BZ3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.</PubMed_Title>
      <Author>Roberts, W.G., et al.</Author>
      <Journal>Cancer Res.(2008)68:1935-1944</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18339875?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CD4 endocytosis motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase</PDB_Title>
      <PDB_ID>3B71</PDB_ID>
      <Resolution>2.82</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B71</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the interaction between focal adhesion kinase and CD4.</PubMed_Title>
      <Author>Garron, M.L., et al.</Author>
      <Journal>J.Mol.Biol.(2008)375:1320-1328</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18078954?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Focal Adhesion Kinase Domain with 2 molecules in the Asymmetric Unit Complexed with ADP and ATP</PDB_Title>
      <PDB_ID>2IJM</PDB_ID>
      <Resolution>2.19</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2IJM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of Focal Adhesion Kinase Catalytic Domain Complexed with ATP and Novel 7H-Pyrrolo [2,3-d] pyrimidine Inhibitor Scaffolds</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Focal Adhesion Kinase catalytic domain in complex with an allosteric binding pyrazolobenzothiazine compound.</PDB_Title>
      <PDB_ID>4I4F</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I4F</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04870007</ASD_Ligand>
      <PubMed_Title>Structure-based discovery of cellular-active allosteric inhibitors of FAK.</PubMed_Title>
      <Author>Tomita, N., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2013)23:1779-1785</Journal>
      <PubMed_ID>23414845</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Focal Adhesion Kinase (FAK)</PDB_Title>
      <PDB_ID>1MP8</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MP8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography</PubMed_Title>
      <Author>Nowakowski, J., et al.</Author>
      <Journal>Structure(2002)10:1659-1667</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12467573?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Paxillin LD2 motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase</PDB_Title>
      <PDB_ID>1OW8</PDB_ID>
      <Resolution>2.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OW8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular Recognition of Paxillin LD Motifs     by the Focal Adhesion Targeting Domain</PubMed_Title>
      <Author>Hoellerer, M.K., et al.</Author>
      <Journal>Structure(2003)11:1207-1217</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14527389?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Focal Adhesion Kinase catalytic domain in complex with novel allosteric inhibitor</PDB_Title>
      <PDB_ID>4EBV</PDB_ID>
      <Resolution>1.67</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4EBV</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04870001</ASD_Ligand>
      <PubMed_Title>Discovery and characterization of novel allosteric FAK inhibitors.</PubMed_Title>
      <Author>Iwatani, M., et al.</Author>
      <Journal>Eur.J.Med.Chem.(2013)61:49-60</Journal>
      <PubMed_ID>22819505</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Focal Adhesion Kinase catalytic domain in complex with hinge binding pyrazolobenzothiazine compound.</PDB_Title>
      <PDB_ID>4I4E</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I4E</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04878002</ASD_Ligand>
      <PubMed_Title>Structure-based discovery of cellular-active allosteric inhibitors of FAK.</PubMed_Title>
      <Author>Tomita, N., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2013)23:1779-1785</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/23414845?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Paxillin LD4 motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase</PDB_Title>
      <PDB_ID>1OW7</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OW7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular Recognition of Paxillin LD Motifs   by the Focal Adhesion Targeting Domain</PubMed_Title>
      <Author>Hoellerer, M.K., et al.</Author>
      <Journal>Structure(2003)11:1207-1217</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14527389?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Focal Adhesion Kinase catalytic domain in complex with novel allosteric inhibitor</PDB_Title>
      <PDB_ID>4EBW</PDB_ID>
      <Resolution>2.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4EBW</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04878002</ASD_Ligand>
      <PubMed_Title>Discovery and characterization of novel allosteric FAK inhibitors.</PubMed_Title>
      <Author>Iwatani, M., et al.</Author>
      <Journal>Eur.J.Med.Chem.(2013)61:49-60</Journal>
      <PubMed_ID>22819505</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04062</Pathway_ID>
      <Pathway_Title>Chemokine signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04810</Pathway_ID>
      <Pathway_Title>Regulation of actin cytoskeleton</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell motility</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05222</Pathway_ID>
      <Pathway_Title>Small cell lung cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05100</Pathway_ID>
      <Pathway_Title>Bacterial invasion of epithelial cells</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04370</Pathway_ID>
      <Pathway_Title>VEGF signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05202</Pathway_ID>
      <Pathway_Title>Transcriptional misregulation in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04670</Pathway_ID>
      <Pathway_Title>Leukocyte transendothelial migration</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04012</Pathway_ID>
      <Pathway_Title>ErbB signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04360</Pathway_ID>
      <Pathway_Title>Axon guidance</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Development</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04510</Pathway_ID>
      <Pathway_Title>Focal adhesion</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04360</Pathway_ID>
      <Pathway_Title>Axon guidance</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Development</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.dg.j.b.b.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1k04</CATH_URL>
  </Fold>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.10.2</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/10/2.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD04870001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04870002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04870003</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04870004</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04870007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04878002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>